Ambu (AMBU) CMD 2025 summary

Strategic direction and market outlook

• Launched the ZOOM AHEAD strategy to achieve global leadership in single-use endoscopy, building on prior successful strategies and profitable growth.

• Focused on four core segments: respiratory, urology, ENT, and GI, with respiratory and urology as key growth drivers and GI as a long-term opportunity.

• Strategic themes include customer centricity, innovation, scalable business platform, and a culture of empowerment and growth.

• Emphasis on expanding digital solutions (Endo Intelligence), sustainability leadership, and leveraging a broad portfolio to drive standardization and customer loyalty.

• M&A will be pursued selectively to accelerate Endoscopy Solutions growth, focusing on technology, capabilities, and adjacencies that enhance the core offering.

Financial guidance and growth targets

• Increased long-term organic revenue growth target to 11%-13% CAGR through FY 2029/2030, with Endoscopy Solutions expected to deliver 15%-20% CAGR.

• EBIT margin targeted at over 20% by FY 2029/2030, with a milestone of around 20% by FY 2027/2028, allowing for growth investment trade-offs.

• Cash conversion expected to exceed 40% across the strategy period, supported by margin expansion, productivity gains, and disciplined capital allocation.

• Anesthesia and patient monitoring growth ambitions raised to 3%-5% CAGR, reflecting improved commercial execution and market position.

• Maintains FY 2024/25 outlook: organic revenue growth of 12-14% and EBIT margin of 13-15%.

Market opportunities and business developments

• Single-use endoscopy market projected to grow at 20% CAGR, reaching over DKK 15 billion in five years, with significant runway in all core segments.

• Holds over 60% share in single-use endoscopy, with the broadest portfolio and largest direct commercial footprint.

• Clinician preference for single-use driven by efficiency, economics, and infection control; adoption supported by strong clinical evidence and customer engagement.

• Innovation pipeline includes next-generation scopes, AI-enabled Endo Intelligence, and digital integration for improved clinical outcomes and workflow efficiency.

• Leads the shift to single-use endoscopy, currently holding market leadership across four business areas.